| Website | zealandpharma.com |
| Category | BioTech |
| Phone | 45-88-77-36-00 |
| info@zealandpharm... | |
| Employees | |
| Description | Biotechnology company |
Zealand Pharma A/S (NASDAQ OMX Copenhagen: ZEAL) is a biotechnology company based in Copenhagen, Denmark. Zealand Pharma specializes in the discovery, optimization and development of novel peptide drugs and has a broad and mature pipeline of drug candidates identified through its own drug discovery activities. The company’s focus lies in the field of diabetes/metabolic diseases, and its lead drug invention is lixisenatide (Lyxumia® 1), a once-daily GLP-1 agonist, which is licensed to Sanofi for the treatment of Type 2 diabetes. Lixisenatide is currently under regulatory review in a large number of countries globally, and in November 2012 the European Committee for Human Medicinal Products issued a positive recommendation for approval of the product in Europe.
